PHARMACOLOGICAL AND SURGICAL TREATMENT OF OBESITY: INTEGRATING THE ROLES OF INFLAMMATION AND GUT DYSBIOSIS- REVIEW
DOI:
https://doi.org/10.31435/ijitss.1(49).2026.4791Keywords:
Obesity, Treatment, Inflammation, Microbiota, Bariatric SurgeryAbstract
Obesity is a metabolic disease characterized by chronic systemic inflammation and dysbiosis of gut microbiota. This review explores relationships between obesity, inflammatory pathways, and gut microbiome composition within a clinical perspective, concentrating on pharmacological and surgical options. Current therapeutic strategies consist of GLP-1 receptor agonists, orlistat, naltrexone-bupropion combination therapy, and bariatric surgery. Significantly, therapeutic advantages go far beyond weight decrease to consist of improved microbial diversity, decreased inflammation (reflected as a decrease in inflammatory markers such as CRP, IL-6, and TNF-α), and metabolic outcomes. The present review demonstrates that successful obesity therapy requires both the normalisation of gut microbial function and the elimination of systemic inflammation, underscoring the significance of microbiota-related modalities for total obesity treatment.
References
Abad-Jiménez, Z., Asensio, E. M., Latorre, M., Fernández-Monge, A., Monleón, D., Pérez-Guillermo, M., & García-Gómez, M. E. (2022). Roux-en-Y gastric bypass modulates AMPK, autophagy and inflammatory response in leukocytes of obese patients. Biomedicines, 10(2), 430. https://doi.org/10.3390/biomedicines10020430
Abumrad, N. N., & Albaugh, V. L. (2018). Surgical treatment of obesity. F1000Research, 7, 1782. https://doi.org/10.12688/f1000research.13515.1
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021). A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs, 81(9), 1019–1034. https://doi.org/10.1007/s40265-021-01499-w
Apovian, C. M. (2015, December). Naltrexone/bupropion for the treatment of obesity and obesity with type 2 diabetes. Future Medicine. https://doi.org/10.2217/fca.15.79
Bajaj, H., et al. (2020, December). Extended-release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14284
Bialecka-Florjanczyk, E., Fabiszewska, A. U., Krzyczkowska, J., & Kurylowicz, A. (2018). Synthetic and natural lipase inhibitors. Mini-Reviews in Medicinal Chemistry, 18(8), 666–684. https://doi.org/10.2174/1389557516666160630123356
Billes, S. K., Sinnayah, P., & Cowley, M. A. (2014a). Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss. Pharmacological Research, 84, 1–11. https://doi.org/10.1016/J.PHRS.2014.04.004
Bode, B. (2012). An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Research and Clinical Practice, 97(1), 27–42. https://doi.org/10.1016/j.diabres.2011.12.015
Bonfioli, G., Capotosto, V., Gualdani, E., Nati, G., Scappaticci, L., Zoli, E., & Marini, S. (2024). GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction. Heart Failure Reviews. https://doi.org/10.1007/s10741-024-10450-6
Chen, M., Han, J., Shi, D., & Yang, B. (2025). A meta-analysis of changes in gut microbiota structure following bariatric surgery. International Journal of Surgery. https://doi.org/10.1097/JS9.0000000000002977
Cheng, Z., Zhang, L., Yang, L., & Chu, H. (2022). The critical role of gut microbiota in obesity. Frontiers in Endocrinology, 13, 1025706. https://doi.org/10.3389/fendo.2022.1025706
Wong, C. K., & Drucker, D. J. (2025). Anti-inflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. The Journal of Clinical Investigation. https://doi.org/10.1172/jci194751
De La Garza, A. L., Milagro, F. I., Boque, N., Campión, J., & Martínez, J. A. (2011). Natural inhibitors of pancreatic lipase as new players in obesity treatment. Planta Medica, 77(8), 773–785. https://doi.org/10.1055/s-0030-1270924
Di Vincenzo, F., De Caro, C., Sforza, E., Zazzara, V., Fornaro, M., Fusar-Poli, L., & Manti, S. (2025). Psychopharmacological therapy positively modulates disease activity in inflammatory bowel disease: A systematic review. International Journal of Molecular Sciences, 26(13), 6514. https://doi.org/10.3390/ijms26136514
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001
Du, L., Duan, Y., Liu, W., Yin, J., Liu, H., & Zhou, B. (2021). Lipopolysaccharides derived from gram-negative bacterial pool of human gut microbiota promote inflammation and obesity development. International Reviews of Immunology, 41(1), 1–11. https://doi.org/10.1080/08830185.2021.1996573
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023). Obesity management in adults. JAMA, 330(20), 2004–2016. https://doi.org/10.1001/jama.2023.19897
Feng, X., Lin, Y., Zhuo, S., Dong, Z., Shao, C., Ye, J., & Zhong, B. (2023). Treatment of obesity and metabolic-associated fatty liver disease with a diet or orlistat: A randomized controlled trial. American Journal of Clinical Nutrition, 117(4), 658–666. https://doi.org/10.1016/j.ajcnut.2023.02.008
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/nejmoa2107519
Furet, J., Kong, L. C., Tap, J., Poitou, C., Basdevant, A., Bouillot, J. L., Mariat, D., Corthier, G., Doré, J., & Clément, K. (2010). Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss. Diabetes, 59(12), 3049–3057. https://doi.org/10.2337/db10-0253
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Dyal, L., Hall, S., Rao-Melacini, P., Wong, G., Avezum, A., Basile, J., Chung, N., ... Zigrang, W. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. The Lancet, 394(10193), 121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
Ghusn, W., De La Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022). Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Network Open, 5(9), e2231982. https://doi.org/10.1001/jamanetworkopen.2022.31982
Grilo, C., Lydecker, J. A., Fineberg, S., Moreno, J. O., Ivezaj, V., & Gueorguieva, R. (2022, October). Naltrexone-bupropion and behavior therapy, alone and combined, for binge-eating disorder: Randomized double-blind placebo-controlled trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.20220267
Grilo, C., Lydecker, J. A., & Gueorguieva, R. (2023, June). Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: Randomized double-blind placebo-controlled trial. Psychological Medicine. https://doi.org/10.1017/S0033291723001800
Holst, J. J. (2007). The physiology of glucagon-like peptide 1. Physiological Reviews, 87(4), 1409–1439. https://doi.org/10.1152/physrev.00034.2006
Ion, R., Bota, I. M., Botezan, M. C., Suciu, M. F., Munteanu, M. A., & Muntean, M. V. (2024). Short-term changes in TNF-alpha, IL-6 and adiponectin following bariatric surgery in Caucasian obese adults: An observational case-control study. Medicina, 60(11), 11789. https://doi.org/10.3390/medicina60111789
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038
Li, J., Zhou, F., Li, S., Wang, H., & Liu, G. (2025). Bupropion administration significantly impacts the gut microbiome, serum metabolites, and immune factors in chronic stress depression rats. Journal of Affective Disorders, 378, 120457. https://doi.org/10.1016/j.jad.2025.120457
Singh, K., Singh, V., Gupta, S., & Singh, V. P. (2024). Rebalancing the gut: Glucagon-like peptide-1 agonists as a strategy for obesity and metabolic health. Cureus, 16(7), e64738. https://doi.org/10.7759/cureus.64738
Gofron, K. K., Jaworska-Adamu, A., Ratajczak, M., Wojciak, P., Winiarczyk, M., Dziewulska, A., Piekoszewska, A., & Ostanek, M. (2025). Effects of GLP-1 analogues and agonists on the gut microbiota: A systematic review. Nutrients, 17(8), 1303. https://doi.org/10.3390/nu17081303
Kheirvari, M., Dadkhah Nikroo, N., Jaafarinejad, H., Farsimadan, M., Eshghjoo, S., Hosseini, S., & Anbara, T. (2020). The advantages and disadvantages of sleeve gastrectomy: Clinical laboratory to bedside review. Heliyon, 6(2), e03496. https://doi.org/10.1016/j.heliyon.2020.e03496
Kim, K. K., Haam, J. H., Kim, B. T., Kim, E. M., Park, J. H., Rhee, S. Y., Jeon, E., Kang, E., Nam, G. E., Koo, H. Y., Lim, J. H., Jeong, J. E., Kim, J. H., Kim, J. W., Park, J. H., Hong, J. H., Lee, S. E., Min, S. H., Kim, S. J., ... Lee, C. B. (2023). Evaluation and treatment of obesity and its comorbidities: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity. Journal of Obesity & Metabolic Syndrome, 32(1), 1–25. https://doi.org/10.7570/jomes23016
Koutoukidis, D. A., Tsilidis, K. K., Nane, R. M., & Zaki, M. Y. (2022). The association of weight loss with changes in the gut microbiota diversity, composition, and intestinal permeability: A systematic review and meta-analysis. Gut Microbes, 14(1), 2020068. https://doi.org/10.1080/19490976.2021.2020068
Kwon, Y. J., Kwon, G. E., Lee, H. S., Choi, M. H., & Lee, J. W. (2022). The effect of orlistat on sterol metabolism in obese patients. Frontiers in Endocrinology, 13, 824269. https://doi.org/10.3389/fendo.2022.824269
Le Roux, C. W., Fils-Aimé, N., Camacho, F., Gould, E., & Barakat, M. (2022). The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy. EClinicalMedicine, 49. https://doi.org/10.1016/j.eclinm.2022.101436
Liang, Y., Wang, W., Luo, C., Han, Z., Li, S., Zhao, M., & Yang, C. (2024). Fu loose tea administration ameliorates obesity in high-fat diet-fed C57BL/6J mice: A comparison with Fu brick tea and orlistat. Foods, 13(2), 206. https://doi.org/10.3390/foods13020206
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/nejmoa2307563
Lin, Q., Xue, Y., Zou, H., Ruan, Z., Ung, C. O. L., & Hu, H. (2022). Efficacy and safety of liraglutide for obesity and people who are overweight: A systematic review and meta-analysis of randomized controlled trials. Expert Review of Clinical Pharmacology, 15(12), 1435–1446. https://doi.org/10.1080/17512433.2022.2130760
Louis, S., Tappu, R. M., Furet, J.-P., & Westermann, C. (2016). Characterization of the gut microbial community of obese patients following a weight-loss intervention using whole metagenome shotgun sequencing. PLoS ONE, 11(2), e0149564. https://doi.org/10.1371/journal.pone.0149564
Luesma, M. J., Fernando, J., Cantarero, I., Lucea, P., & Santander, S. (2022). Surgical treatment of obesity. Special mention to Roux-en-Y gastric bypass and vertical gastrectomy. Frontiers in Endocrinology, 13, 867838. https://doi.org/10.3389/fendo.2022.867838
Maggard, M. A., Shugarman, L. R., Suttorp, M., Maglione, M., Sugarman, H. J., Livingston, E. H., Nguyen, N. T., Li, Z., Mojica, W. A., Hilton, L., Rhodes, S., Morton, S. C., & Shekelle, P. G. (2005). Meta-analysis: Surgical treatment of obesity. Annals of Internal Medicine, 142(7), 547–559. https://doi.org/10.7326/0003-4819-142-7-200504050-00013
Min, T., Han, S., Lim, Y. J., Kim, S. W., Min, K. W., & Kim, B. J. (2020). Temporal effects of bariatric surgery on adipokines, inflammation and oxidative stress in subjects with impaired glucose homeostasis at 4 years of follow-up. Obesity Surgery, 30(1), 143–152. https://doi.org/10.1007/s11695-019-04377-3
Mishra, S., Luthra, R., Khan, M. I., & Ahsan, H. (2023). A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut. Gut, 72(3), 544–555. https://doi.org/10.1136/gutjnl-2022-327365
Nachawi, N., Rao, P. P., & Makin, V. (2022). The role of GLP-1 receptor agonists in managing type 2 diabetes. Cleveland Clinic Journal of Medicine, 89(8), 445–454. https://doi.org/10.3949/ccjm.89a.21110
Paganelli, F. L., da Silva, L. V., Arantes, V., de Oliveira, A. L. S., Vilela, R. M., & de Mello, M. T. (2019). Roux-Y gastric bypass and sleeve gastrectomy directly change gut microbiota composition independent of surgery type. Scientific Reports, 9(1), 10811. https://doi.org/10.1038/s41598-019-47332-z
Panigrahi, S. K., Meece, K., & Wardlaw, S. L. (2019). Effects of naltrexone on energy balance and hypothalamic melanocortin peptides in male mice fed a high-fat diet. Journal of the Endocrine Society, 3(3), 590–601. https://doi.org/10.1210/js.2018-00379
Pérez-Rubio, M. J., García-Alcázar, A., Carvajal-García, A., Lujan-Martínez, M. J., González-Segura, R., & Valdés-Hernández, C. (2023). Gut microbiota and plasma bile acids associated with non-alcoholic fatty liver disease resolution in bariatric surgery patients. Nutrients, 15(14), 3187. https://doi.org/10.3390/nu15143187
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. H. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/nejmoa1411892
Potrykus, M., Dworacka, M., Struk, E., & Żukowski, P. (2022). Intestinal barrier disorders and metabolic endotoxemia in obesity: Current knowledge. Archives of Medical Science - Atherosclerotic Diseases, 7, e12–e20. https://doi.org/10.2478/ahem-2022-0008
Randeni, N., Mudalige, S., K, B., & B, H. (2024). A comprehensive review of the triangular relationship among diet-gut microbiota-inflammation. International Journal of Molecular Sciences, 25(17), 9366. https://doi.org/10.3390/ijms25179366
Roudbaraki, S. N., Salimi, M., Esmailpour, S., & Mohammadi, F. (2025, September). Efficacy of naltrexone and bupropion combination in patients with binge eating disorder: A systematic review and meta-analysis. Eating and Weight Disorders. https://doi.org/10.1007/s40519-025-01786-5
Rosenstock, J., Raccah, D., Koranyi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013). Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care, 36(10), 2945–2951. https://doi.org/10.2337/dc12-2709
Scheithauer, T. P. M., Badi, M., & van der Meer, P. A. (2020). Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Frontiers in Immunology, 11, 571731. https://doi.org/10.3389/fimmu.2020.571731
Scott, L. J. (2020). Dulaglutide: A review in type 2 diabetes. Drugs, 80(2), 173–189. https://doi.org/10.1007/s40265-020-01260-9
Soroceanu, R. P., Rad, O. I., Rad, P. E., Almas, A. R., & Sîrbu, A. I. (2025). The impact of bariatric surgery on gut microbiota composition and diversity: A longitudinal analysis using 16S rRNA sequencing. International Journal of Molecular Sciences, 26(16), 7933. https://doi.org/10.3390/ijms26167933
Turpin, T., M, C., K, K., S, B., C, K., & B, B. (2023). Adipokines and bacterial metabolites: A pivotal molecular bridge linking obesity and gut microbiota dysbiosis to target. Biomolecules, 13(12), 1692. https://doi.org/10.3390/biom13121692
Valladales-Restrepo, L. F., Sánchez-Ramírez, N., Usma-Valencia, A. F., Gaviria-Mendoza, A., Machado-Duque, M. E., & Machado-Alba, J. E. (2023). Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity. Expert Opinion on Pharmacotherapy, 24(4), 485–492. https://doi.org/10.1080/14656566.2023.2178900
Verma, S., Poulter, N. R., Bhatt, D. L., Bain, S. C., Buse, J. B., Leiter, L. A., Nauck, M. A., Pratley, R. E., Zinman, B., Ørsted, D. D., Fries, T. M., Rasmussen, S., & Marso, S. P. (2018). Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from the LEADER trial. Circulation, 138(25), 2872–2884. https://doi.org/10.1161/CIRCULATIONAHA.118.034516
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., Ahmad, N. N., & Forrester, T. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: The SURMOUNT-3 phase 3 trial. Nature Medicine, 29(11), 2818–2828. https://doi.org/10.1038/s41591-023-02597-w
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183
Yan, L., Wu, P., Liu, Y., Zhang, W., Chen, C., Huang, Q., Wang, H., & Liu, D. (2025). Orlistat ameliorates lipid dysmetabolism in high-fat diet-induced mice via gut microbiota modulation. Frontiers in Microbiology, 16, 1480500. https://doi.org/10.3389/fmicb.2025.1480500
Yoon, J. Y., & Arau, R. T. (2021). The efficacy and safety of endoscopic sleeve gastroplasty as an alternative to laparoscopic sleeve gastrectomy. Clinical Endoscopy, 54(1). https://doi.org/10.5946/CE.2021.019
Zheng, J. (2025). Nutritional correlation between gut microbiota and obesity. None. https://doi.org/10.61173/mmys9z60
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Karolina Zarówna, Weronika Pura, Jakub Mazur, Jakub Marciniak, Mateusz Kosowski, Dominika Matecka, Wiktor Śliwiński, Daniel Chołuj
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
